Please login to the form below

Not currently logged in
Email:
Password:

myelofibrosis

This page shows the latest myelofibrosis news and features for those working in and with pharma, biotech and healthcare.

Incyte’s JAK inhibitor cream clears second eczema trial

Incyte’s JAK inhibitor cream clears second eczema trial

Ruxolitinib is already on the market in oral form under the Jakafi/Jakavi brand names as a treatment for myelofibrosis, a type of bone marrow cancer.

Latest news

  • BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

    It was cleared for use in myelofibrosis – a rare bone marrow disorder. ... Some analysts have predicted that Inrebic could also become a $1bn product in myelofibrosis, despite a black-box warning on its label for a serious and life-threatening brain

  • Roche agrees $1.4bn takeover of fibrosis specialist Promedior Roche agrees $1.4bn takeover of fibrosis specialist Promedior

    associated with scarring of the lungs, as well as early-stage results in myelofibrosis. ... That mechanism suggests PRM-151 could have potential in a range of diseases characterised by fibrosis, including myelofibrosis – a haematological cancer that

  • France’s Innate Pharma eyes $100m Nasdaq IPO France’s Innate Pharma eyes $100m Nasdaq IPO

    That includes continuing clinical development of anti-KIR3DL2 antibody IPH4102 for the treatment of patients with Sézary syndrome – a form of cutaneous T cell lymphoma (CTCL) – as well as myelofibrosis and

  • BMS buoyed by FDA approval of Celgene’s myelofibrosis drug BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

    Currently in the middle of merger. After a turbulent development, Celgene has finally claimed FDA approval for Inrebic, its new drug for rare bone marrow disorder myelofibrosis. ... That deal is worth up to $7bn but is weighted to fedratinib’s

  • Triplet approvals for myeloma boost Celgene in Q2 Triplet approvals for myeloma boost Celgene in Q2

    Also nearing the market are fedratinib for myelofibrosis which could be approved in September, luspatercept for myelodysplastic syndromes – with an FDA decision due next April – and ozanimod for multiple sclerosis, which

More from news
Approximately 9 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis

  • Deal Watch January 2018

    The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company -  remaining 90%. 9

  • Pharma deals in August 2015 Pharma deals in August 2015

    Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐2 protein for idiopathic pulmonary fibrosis and myelofibrosis.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal

  • NICE and ‘ultra orphans’ NICE and ‘ultra orphans’

    It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100,

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics